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Background: IgA nephropathy (IgAN) is the most common glomerulonephritis, which may also coexist with other
diseases. We present two patients with an unusual coincidence of IgAN and Fabry disease (FD).
Case presentation: A 26 year-old man underwent a renal biopsy in February 2001. Histopathology showed very
advanced IgAN and vascular changes as a result of hypertension. Because of his progressive renal insufficiency the
patient began hemodialysis in August 2001. By means of the blood spot test screening method the diagnosis of FD
was suspected. Low activity of alpha-galactosidase A in the patient’s plasma and leukocytes and DNA analysis
confirmed the diagnosis of FD. Enzyme replacement therapy started in July 2004. Then the patient underwent
kidney transplantation in November 2005. Currently, his actual serum creatinine level is 250 μmol/l. Other organ
damages included hypertrophic cardiomyopathy, neuropathic pain and febrile crisis. After enzyme replacement
therapy, myocardial hypertrophy has stabilized and other symptoms have disappeared. No further progression of
the disease has been noted.
The other patient, a 30 year-old woman, suffered from long-term hematuria with a good renal function. Recently,
proteinuria (2.6 g/day) appeared and a renal biopsy was performed. Histopathology showed IgAN with remarkably
enlarged podocytes. A combination of IgAN and a high suspicion of FD was diagnosed. Electron microscopy
revealed dense deposits in paramesangial areas typical for IgAN and podocytes with inclusive zebra bodies and
myelin figures characteristic of FD. FD was confirmed by the decreased alpha-galactosidase A activity in plasma and
leukocytes and by DNA and RNA analysis. Enzyme replacement therapy and family screening were initiated.
Conclusions: Our results emphasize the role of complexity in the process of diagnostic evaluation of kidney biopsy
samples. Electron microscopy represents an integral part of histopathology, and genetic analysis plays a more and
more important role in the final diagnosis, which is followed by causal treatment.
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IgA nephropathy (IgAN) is the most common glomerulo-
nephritis, which may also coexist with other diseases. Diag-
nosis of IgAN depends on the demonstration of mesangial
IgA-dominant staining (by immunofluorescence or by
immunohistochemistry). Weak staining for IgG and/or
IgM is also detected in about 50% of cases. Early compo-
nents of the classical complement pathway, namely
C1q is frequently absent. However, C3 is detected in
more than 90% of cases of primary IgAN. Microscopic* Correspondence: ditama@centrum.cz
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identify 30–40% of pts with IgAN. The clinical presenta-
tion of macroscopic hematuria is commonly provoked
by upper respiratory tract infection. Some pts already
have renal impairment and hypertension at initial presen-
tation [1].
Fabry disease (FD) is an X-linked disorder of glycosphin-
golipid catabolism caused by a deficiency of the lysosomal
enzyme alpha-galactosidase A. This enzymatic defect leads
to a progressive systemic accumulation of glycosphingoli-
pids, mainly globotriaosylceramide, in lysosomes of cells
of different tissues. It results in many clinical symptoms
such as angiokeratomas, hypohidrosis, neuropathic pains,
corneal opacities, renal and cardiovascular diseases. FDntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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gous females have variable levels of alpha-galactosidase A
activity with a wide range of clinical signs [2].
The birth prevalence of FD in the Czech population
was calculated to be 0,52 per 100 000 live births (or 1
per 100 000 male live births) and 0,77 per 100 000 live
births for hemizygous and heterozygous female, respect-
ively [3]. We present two patients with very rare coinci-
dence of IgAN and FD.
Case presentation
A 26-year-old man was admitted to our Department of
Nephrology for a headache and newly ascertained
advanced renal insufficiency (serum creatinine level
606 μmol/L, urea nitrogen 21 mmol/L, creatinine clear-
ance 0.29 mL/s) with blended urinalysis (proteinuria
5.6 g/day, microhematuria – 25/ μl). Any serious dis-
eases were noted at the time of admission to the hospital
in February 2001. When he was sixteen he was hospita-
lized for a headache and uncertain abnormality of uri-
nalysis but after this incident the patient was not
examined and followed by the doctors. The patient did
not take any regular treatment or addictive drugs, he
abstained from alcohol and was a nonsmoker. There was
an interesting statement in his family history about his
4-year older brother, who was hemodialysed for four
years due to end stage renal disease probably evoked
by addictive drugs (without verification by a renal bi-
opsy) and he died at the age of 29 years. His five brothers
and two sisters had no symptoms for renal or other dis-
eases. The patient’s father died of prostate cancer at
the age of 35 and he had no cardiovascular or renal dis-
ease, the patient’s mother suffered from a heart attack
and epilepsy.
Physical examination of the patient revealed arterial
hypertension (blood pressure was 150/100 mmHg, pulse
was 70 beats/min), body temperature was 36.1°C, BMI
25, and no other abnormalities were found by clinical
examination.
The levels of renal parameters at the time of admission
to the hospital are mentioned above. Ultrasound of ab-
domen detected bilateral smaller kidney (length 98 mm
with an unclear structure). Laboratory results showed
serum level of potassium 5.3 mmol/L, hyperphosphatae-
mia 2.1 mmol/L, total protein 67 g/L, albumin 43 g/L,
metabolic acidosis (pH 7.2, HCO3 16.8 mmol/L, BE –
6.8 mmol/L), mild anaemia (the level of hemoglobin
125 g/L), mild hyperuricaemia (the level of uric acid
448 mmol/L), dyslipoproteinaemia with an elevation of
LDL cholesterol (total cholesterol 7.5 mmol/L, LDL
cholesterol 4.8 mmol/L, triglycerides 3.11 mmol/L),
results of liver function tests were negative, urinalysis
showed a pH 6, microhematuria – 25/ μl, the 24-h pro-
tein excretion was 5.6 g/d). Immunology tests werenormal (immunoglobulin A, immunoglobulin M, im-
munoglobulin G, C3 and C4 complement, antinuclear
antibodies, antibodies to extractable nuclear antigens,
anti-neutrophil cytoplasmic antibodies, immune com-
plexes). The electrocardiogram revealed the signs of left
ventricle hypertrophy.
The patient underwent renal biopsy. In a renal biopsy
sample, immunofluorescence and light microscopy
[Figure 1a,1b] showed an advanced form of mesangio-
proliferative IgAN with marked scarring and epithelial
crescents (in two glomeruli of the 12, the remaining 10
glomeruli were completely sclerotic) and vascular changes
as a part of hypertension (electron microscopy was not
performed because only sclerotic glomerulus was present
in the sample). FD was not identified at that time. Blood
pressure was well regulated by means of antihyperten-
sive treatment (angiotensin-converting enzyme inhibitors,
beta-blockers, diuretics). The regimen with corticosteroids
(Prednisone 0.5 mg/kg) was initiated because of the age of
the patient and suspected signs of the disease activity in
the renal biopsy sample even though the possible in-
fluence of hypertension played a role in the occurrance of
epithelial crescents. Subsequently, because of his progres-
sive renal insufficiency the patient started to be hemodia-
lysed in August 2001 (six months after renal biopsy) and
corticosteroids were discontinued.
By means of the screening method in dried blood
spots in 2003 [4] a diagnosis of FD was suspected. Exten-
sive tests for FD were implemented. Deficient activity of
alpha-galactosidase A in the patient’s plasma (patient
0,47 nmol.ml-1.h-1, normal range 2.4 - 11.3 nmol.ml-1.h-1)
and leukocytes (patient 0.23 nmol.mg-1.h-1, normal range
30–77 nmol.mg-1.h-1) confirmed the diagnosis of FD.
After the patient’s informed consent was obtained muta-
tion analysis (Sanger sequencing and RFLP method) was
performed. We identified a missense mutation c.950 T>C
(p.Ile317Thr) in exon 6. This mutation was previously
found in an unrelated FD patient [5]. With this knowledge
we performed additional electron microscopy from archive
paraffin embedded kidney tissue [Figure 1c] and addition-
ally showed dense deposits in paramesangial areas as a
part of IgAN, and podocytes with inclusions of so-called
zebra bodies and myelin figures characteristic of FD. The
enzyme replacement therapy started in July 2004 and still
continues. The patient underwent kidney transplantation
in November 2005. Currently, the actual serum creatinine
level is 250 μmol/L without the necessity of dialysis.
Other organ damages included hypertrophic cardio-
myopathy. After the diagnosis of the coincidence of FD
and IgAN was assessed we asked the patient about the
possible clinical symptoms in his history related to FD
and we found two typical signs such as febrile crisis and
neuropathic pain in the extremities. Typical symptoms
of FD – angiokeratomas and corneal changes – were not
Figure 1 a. Immunofluorescence with IgA positive staining in the mesangium, which is diagnostic for IgAN. b. Advanced lesion with
diffuse interstitial fibrosis and sclerotic glomerulus. IgAN was confirmed by immunofluorescence. No swollen podocytes indicative of FD are seen
(Jones methenamine silver stain; high power field). c. Electron microscopy from paraffin embedded tissue. Small dense deposits in mesangial
area. Simultaneously lamellated lipid inclusions (so-called myeloid bodies) are shown.
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(febrile and painful crisis, neuropathy, hypertrophic car-
diomyopathy and Fabry nephropathy) supported the diag-
nosis of FD. On enzyme replacement therapy myocardial
hypertrophy has stabilised, febrile crisis and neuropathic
pain in the extremities have disappeared. To date, no
other progression of the disease has been noted. After the
informed consent was obtained, mutation analysis of the
GLA gene was performed in 12 relatives, using the direct
sequencing. Other 8 relatives were newly diagnosed with
FD [3 hemizygous and 5 heterozygous, Figure 2].
The second, a 30-year-old woman, suffered from long-
term hematuria with a good renal function. Due to
increasing proteinuria (2.6 g/day) appeared and a renal
biopsy was performed. Histopathology showed IgAN
with remarkably enlarged podocytes. IgAN and a high





Figure 2 Pedigree of the family of the first patient.evaluation using immunofluorescence and light micros-
copy [Figure 3a, 3b]. Electron microscopy [Figure 3c,
semithin section] revealed dense deposits in paramesan-
gial areas typical of IgAN and podocytes with inclusive
zebra bodies and myelin-like bodies characteristic of FD.
The activity of alpha-galactosidase A in plasma was
within the range of control values (3.3 nmol.ml-1.h-1,
normal range 2.4 - 11.3 nmol.ml-1.h-1) and was
decreased in leukocytes (26 nmol.mg-1.h-1, normal range
30–77 nmol.mg¯1.h¯1). The diagnosis of FD was con-
firmed by the identification of the GLA gene muta-
tion c.1085C>T (p.Pro362Leu). This mutation was
previously described in an unrelated FD patient [5]. Muta-
tion analysis was performed after the informed consent
was obtained. The mutation analysis also revealed the
diagnosis of FD in the patient’s mother and sister (both
heterozygous) with the same mutation [Figure 4].
Figure 3 a. Positive mesangial IgA staining in immunofluorescence (high power field). b. Light microscopy - glomerulus with remarkably
enlarged podocytes with many vacuoles in their cytoplasm. Swollen lacy cytoplasm of podocytes is indicative of FD (Jones methenamine silver
stain; high power field). Please note, diagnostic IgA deposits in mesangium were shown in immunofluorescence. c. Semithin section stained with
toluidin blue showed characteristic “blue inclusions” mainly in podocytes. These features together with large podocytes with vacuolated
cytoplasm in light microscopy represent a key to the morphological diagnosis of FD.
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changes (cornea verticillata). Other organ defects were not
proved. Enzyme treatment was initiated recently, but we
still can not assess the effect of enzyme replacement treat-
ment (the short duration of enzyme treatment – only one
month).
Discussion
IgAN belongs to the major primary glomerulonephri-
tides worldwide [6,7] but it may also occur as a second-
ary nephropathy as noted above.
FD is an X-linked disease that manifests predominantly
in affected hemizygous men. Heterozygous females may
have various clinical signs from asymptomatic to severe
depending on X-inactivation status [8]. The coexist-
ence of FD with other immune diseases such as
rheumatoid arthritis [9], systemic lupus erythematosus
[9-13] and celiac sprue [14,15] has been noticed in the li-
terature. FD has also been reported with different nephro-
pathies such as granulomatous interstitial nephritis [16],
focal segmental sclerosis [17] and necrotising, crescentic
glomerulonephritis [18].Figure 4 Pedigree of the family of the second patient (the
relatives of the proband’s mother refused the genetic analysis).Six reports of the coincidence of IgAN and FD have
been published. Three of the reports included three he-
terozygous women with proteinuria and hematuria, nor-
mal renal function and without others significant clinical
manifestation of FD [19-21]. The fourth report described
a 28 year-old man from Japan with very low alpha-
galactosidase A activity and low activity of this enzyme
in the patient’s mother [22]. The fifth report referred
to two adolescent sisters heterozygous for FD inherited
from their father with the rapidly progressing proteinuria
in the nephrotic range, glomerular hematuria and the ty-
pical signs of FD [2]. The last case report concerned a
22 year-old Japanese man with proteinuria (1.5 g/day) and
normal serum creatinine level, with hypohidrosis and
neuralgia with fever [23].
Four case reports of the coexistence of IgAN and FD
come from Japan. It is claimed that there are some
differences in prevalence of IgAN among different ethni-
cities [24,25]. IgAN seems to be observed more frequently
in some Asian countries (Japan and China) than in
Europe. This difference could be partly explained by
different renal biopsy policy because the patients with
isolated microscopic hematuria are indicated to renal
biopsy more frequently in Japan in comparison with
Europe or America.
The pathogenesis of IgAN has not yet been still com-
pletely elucidated. It is hypothesized that aberrantly glyco-
sylated galactose-deficient forms with terminal GalNAc or
sialylated GalNAc in the hinge region of IgA1 molecules
are supposed to react with naturally occuring anti-IgG
and anti-IgA1 antibodies and immune complexes are
formed [24]. An elevated serum galactose-deficient IgA1
level was demonstrated to be antecedent to disease but
IgA1 glycosylation abnormalities are not sufficient to
cause IgAN, additional environmental and genetic cofac-
tors are probably required for an activation of immune
complexes and renal injury [24,26,27]. Recent studies
showed that the IgA-CIC, composed of galactose-deficient
IgA1 complexed with antiglycan antibodies, are bound to
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[26,27]. Thus, they play a role in the pathogenesis of IgAN.
Also familial forms of IgAN [28] have been described. A
linkage of IgAN to chromosomes 6q22-q23, 2, 3, 4 and 17
has been demonstrated [29].
The detection of a high level of autoantibodies has
been found in patients with FD [10]. However, specific
link between IgAN and FD has not yet been disclosed. It
has been suggested that glycosphingolipids accumulating
in FD continuously and chronically stimulate the immune
system and induce an autoimmune reaction [30]. Remark-
ably, the glycolipid structure of globotriaosylceramide
[31] resembles nephritogenoside [32], which causes
progressive experimental nephritis similar to IgAN.
Thus, some patients with FD are prone to the develop-
ment of IgAN which may be determined by different ge-
netic and/or environmental factors. We can not also
excluded that two separate Mendelian traits (FD and
IgAN) were segregating in the described families as was
already reported [2]. The specific relationship between
IgAN and FD needs to be revealed by further studies.
Interestingly, the 57-year-old mother of our second
reported patient had no clinical symptoms compared to
her 32 year-old daughter although they had genetically
proved the same mutation. It has been reported that
family members with FD with the same mutation may
have considerably different phenotypes owing to the
influence of additional modifier genes and/or environ-
mental factors [33].
As we mentioned, the suspicion of Fabry nephropathy
can usually be determined by light microscopy due to
enlarged hypertrophic podocytes (only one report con-
firmed ultrastructural findings from electron microscopy
as the first signs suggestive of FD - 21). Nevertheless,
immunofluorescence and light microscopy of the renal
biopsy sample in our first reported patient did not show
features of Fabry nephropathy. Enlarged podocytes with
vacuolated cytoplasms in light microscopy and also blue
bodies in semithin sections (Figure 3c) represent a key
to the diagnosis of FD. However, in advanced stages of
various renal diseases, the majority of glomeruli are
sclerotic and in the remaining glomeruli with large seg-
mental sclerotic lesions are almost no podocytes, and
therefore this diagnostic marker disappears. We were
unable to recognize the features of FD in light micros-
copy and/or in semithin sections even retrospectively in
this case. On the basis of a positive “blood spot screen-
ing” test, we performed additional electron microscopy
from archive paraffin embedded tissue and the result
showed the coincidence of IgAN and FD. This case
emphasized the important role of electron microscopy
in renal pathology even in such a common disease as
IgAN. We would like to emphasize that average age of
end-stage renal disease in FD patients is around 40 to50 years. Two reported patients are young, the hemizy-
gous male is 26 years old and the heterozygous female is
30 years old. The coincidence of two diseases of IgAN
and FD evidently may accelerate the progression of renal
function decline and the combination of IgAN and FD
in young patients should raise our awareness of possible
differential diagnosis.
The signs of active leasions connected with IgAN (epi-
thelial crescents in two glomeruli of a total of 12) were
approved at the time of renal biopsy in our first patient
therefore in addition to the inhibitors of angiotensin
converting enzyme the immunosuppressive treatment
with corticosteroids were initiated (regarding the possi-
bility of the influence of epithelial crescents by hyper-
tension). With respect to grave vascular hypertensive
changes, glomerular sclerosis in association with ex-
tensive tubulointerstitial scarring (65%), deposits IgA
in the mesangium, and typical figures characteristic of
FD as were mentioned, it is not possibly to clearly
say what was the main cause of the end stage renal
disease in this young 26 year-old man. We suppose it
was the combination of IgAN, FD and severe vascular
changes. We want to emphasize the possibility of ini-
tiating of enzyme replacement therapy, which has sta-
bilized myocardial hypertrophy and other symptoms
have disappeared. Several reports have unequivocaly
documented clinical benefits of enzyme replacement
therapy in FD [34,35].
Conclusion
We have reported a rare coincidence of two diseases
IgAN and FD in two Czech patients. Only two case
reports of the coincidence of IgAN and FD have been
published in Caucasians [2,20]. The precise pathogenesis
of the coincidence of these two entities needs to be elu-
cidated by further studies. Nevertheless, our results
emphasize the role of complexity in the process of diag-
nostic evaluation of kidney biopsy samples. Although
enlarged podocytes in light microscopy can lead to
suspicion of a diagnosis of FD, in advanced cases
where glomeruli are predominantly sclerotic this fea-
ture can be invisible. In such cases electron micros-
copy represents the key to diagnosis. Genetic analysis
plays an important role in the final diagnosis and enables
causal enzyme replacement treatment. Diagnosis of FD in
early stages is often very difficult. Therefore, screening
of newborns of FD could be considered a subject for
future discussion.
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